Anti-doping – How to request a Therapeutic Use Exemption (TUE)
Comité Monégasque antidopage
Stade Louis II - Entrée E
13 avenue des Castelans
Monaco Anti-Doping Committee :
06 40 622 500
Principle and conditions
When, as part of their medical treatment, an athlete has to take medication that features on the The 2019 prohibited list , he or she must request a Therapeutic Use Exemption (TUE).
Requests for a TUE will only be considered in the following cases:
- The athlete would experience significant health problems if the substance was not administered or the method was not used as part of treatment for an acute or chronic disease.
- Therapeutic use of the prohibited substance or method would not lead to enhanced performance, apart from that attributable to a return to a normal state of health following treatment for the medical condition.
- There is no reasonable authorised therapeutic alternative to the use of the substance or method that is usually prohibited.
For example, insulin for the treatment of Type 1 Diabetes (insulin dependent).
TUEs apply for the duration of the treatment as prescribed by a doctor, usually for a maximum of two years. It is the athlete's responsibility to note the expiry date of the TUE and request renewal before the expiry date, if necessary.
The special case of Asthma:
All Beta-2 agonists (including their two optical isomers) are prohibited, except for Salbutamol (a maximum of 1600 microgrammes per 24 hours), Formoterol (a maximum of 36 microgrammes per 24 hours) and Salmeterol, when these are inhaled in accordance with the manufacturer's treatment guidelines.
A declaration of use for Salbutamol, Formoterol, Salmeterol and inhaled glucocorticoids, when these are inhaled, is no longer required, in accordance with the International Standard for TUEs.
However, glucocorticoids, Salbutamol, Formoterol or Salmeterol administered orally, intramuscularly, intravenously or rectally are prohibited, and therefore a TUE is required.
Traces of Salbutamol in urine in a concentration above 1000ng/ml or Formoterol in a concentration above 30ng/ml will be presumed not to be for intentional therapeutic use. Therefore, the results of the analysis will be deemed an adverse analytical finding, unless the sportsperson can prove by a controlled pharmacokinetic study that this abnormal result is in fact due to a therapeutic dose.
Obtaining and completing the form
To get this form, you can either:
- Download it here: Therapeutic Use Exemptions (327-0031_01-2015)
Or collect it from the Secretariat of the Centre Médico Sportif
7, avenue des Castelans
Stade Louis II - Entrée G
MC 98000 MONACO
(+377) 92 05 41 11
Ask your doctor to complete the form and provide you with medical evidence
Your doctor must provide the medical information and details of your treatment.
You must attach proof of the diagnosis to your request. The medical evidence must include your family history and the results of any medical examinations, laboratory analyses and medical imaging. Copies of the original reports or letters should be included if possible. The reasoning for the clinical circumstances should be as objective as possible. In the case of non-demonstrable conditions, the request must be supported by an independent medical statement.
Submitting the documents
The documents should be sent in a sealed envelope, marked as confidential, to the Medical Inspector for Sport, Monaco Anti-Doping Committee.
You should keep a copy.
- Ministerial decree no. 2012-105 of 24 February 2012 amending the ministerial decree no. 2003-533 of 21 October 2003 pertaining to prohibited substances or methods and to therapeutic use exemptions
- Ministerial decree no. 2012-104 of 24 February 2012 amending the ministerial decree no. 2003-532 of 21 October 2003 pertaining to the organisation and occurrence of doping controls
- Ministerial decree no. 2012-103 of 24 February 2012 amending the ministerial decree no. 2003-72 of 7 February 2003 implementing the Sovereign Ordinance no. 15.656 of 7 February 2003 instituting a Monegasque Anti-Doping Committee
- Sovereign Ordinance no. 3.674 of 20 February 2012 appointing members of the Monegasque Anti-Doping Committee
- Sovereign Ordinance no. 3.684 du 24 February 2012 amending the Sovereign Ordinance no. 15.656 of 7 February 2003 which instituted a Monegasque Anti-Doping Committee
- Act no. 538 of 12 May 1951 creating and organising a medical inspectorate service for schools and sports players
- Ordinance no. 16.234 of 27 February 2004 giving effect to the agreement of the Council of Europe against drug use, concluded in Strasbourg on 16 November 1989
- Ordinance no. 16.235 of 27 February 2004 giving effect to the additional protocol in the agreement against drug use, signed in Warsaw on 12 September 2002
- Ordinance no. 16.727 of 05 April 2005 giving effect to the Amendment to the appendix of the Agreement of the Council of Europe against drug use, concluded in Strasbourg on 16 November 1989
- Ordinance no. 959 of 07 February 2007 giving effect to the International Convention against Doping in Sport (UNESCO)
- Ministerial Decree no. 2005-375 of 27 July 2005 amending the Ministerial Decree no. 2003-533 of 21 October 2003 pertaining to prohibited substances and methods and to therapeutic use exemptions
- Ministerial Decree no. 2003-531 of 21 October 2003 pertaining to the licensing, swearing in and preliminary and continued training of doctors who are responsible for doping controls
- Sovereign Ordinance No. 5.804, dated 11/04/2016, bringing into force the Prohibited List – International Standard 2016 and the Standards for Granting Therapeutic Use Exemptions – TUE Standard 2016, amending Annexes I and II of the International Convention Against Doping in Sport (UNESCO)